<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04262609</url>
  </required_header>
  <id_info>
    <org_study_id>ONCORTCST2020-1</org_study_id>
    <nct_id>NCT04262609</nct_id>
  </id_info>
  <brief_title>Faecal Incontinence in Prostate Cancer Survivors Treated Whith Radiotherapy</brief_title>
  <official_title>Faecal Incontinence in Prostate Cancer Survivors Treated With Moderately Hypofractionated Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Consorci Sanitari de Terrassa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Consorci Sanitari de Terrassa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to determine the incidence of faecal incontinence in prostate
      cancer survivors treated with moderately hypofractionated radiation therapy and correlate the
      dose received by the anal sphincter with the degree of faecal incontinence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators know that high doses of irradiation in the anal sphincter are associated
      with more chronic fecal leaks in survivors irradiated by normofractionated radiotherapy
      prostate cancer.

      The safe dose of irradiation of the anal sphincter with radiotherapy modern techniques
      (volumetric modulated arc therapy with moderately hypofracctionation) is unknown.

      Urgency and faecal incontinence greatly affects the quality of life of these patients.

      Therefore, it is interesting to implement strategies to protect the anatomical structures
      involved in fecal continence.

      The objective of the study is to determine the incidence of faecal incontinence in prostate
      cancer survivors treated with modern moderately hypofractionated radiation therapy and
      correlate the dose received by the anal sphincter with the degree of faecal incontinence.

      The investigators also want to evaluate the quality of life of these patients
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>faecal incontinence after prostate radiation therapy</measure>
    <time_frame>before radiotherapy (basal)</time_frame>
    <description>grade of faecal incontinence in prostate cancer patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>faecal incontinence after prostate radiation therapy</measure>
    <time_frame>change 2 years after completion of radiotherapy</time_frame>
    <description>grade of faecal incontinence in prostate cancer survivors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>faecal incontinence after prostate radiation therapy</measure>
    <time_frame>change 3 years after completion of radiotherapy</time_frame>
    <description>grade of faecal incontinence in prostate cancer survivors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>faecal incontinence after prostate radiation therapy</measure>
    <time_frame>change 4 years after completion of radiotherapy</time_frame>
    <description>grade of faecal incontinence in prostate cancer survivors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>faecal incontinence after prostate radiation therapy</measure>
    <time_frame>change 5 years after completion of radiotherapy</time_frame>
    <description>grade of faecal incontinence in prostate cancer survivors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life after prostate radiation therapy</measure>
    <time_frame>3 years after completion of radiotherapy</time_frame>
    <description>Quality of life in prostate cancer survivors comparing continents patients and incontinents patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life after prostate radiation therapy</measure>
    <time_frame>5 years after completion of radiotherapy</time_frame>
    <description>Quality of life in prostate cancer survivors comparing continents patients and incontinents patients</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Faecal Incontinence</condition>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated radiotherapy</intervention_name>
    <description>volumetric modulated moderately fractionated arc therapy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Prostate cancer survivors treated in our department by volumetric modulated
        hypofractionated arc therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prostate cancer survivors treated in our department by hypofractionated radiotherapy

        Exclusion Criteria:

          -  Relapse of prostate cancer

          -  Other active cancer

          -  Mental disorder
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Joan Lozano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consorci Sanitari de Terrassa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joan Lozano, MD</last_name>
    <phone>+34 937003690</phone>
    <email>jlozano@cst.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nico Feltes, MD</last_name>
    <phone>+34 937003690</phone>
    <email>nfeltes@cst.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Catalonia</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Joan Lozano, MD</last_name>
      <phone>+34 937003690</phone>
      <email>jlozano@cst.cat</email>
    </contact>
    <contact_backup>
      <last_name>Joan Lozano, MD</last_name>
      <phone>34 937003690</phone>
      <email>jlozano@cst.cat</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Consorci Sanitari de Terrassa</investigator_affiliation>
    <investigator_full_name>Joan Lozano Galan</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>hypofractionated radiotherapy</keyword>
  <keyword>quality of life</keyword>
  <keyword>cancer survivors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

